Enveric Biosciences is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Co.'s pipeline of product candidates and ongoing development programs include: EV104 (Cannabidiol and Celecoxib Conjugate), which is used as the targeted indication of Osteoarthritis; EVM-201, which is used as the targeted indication of anxiety; EVM-301, which is used as the targeted indications of mental health indication; Cannabinoid-Infused Topical Product, which is used as the targeted indication of oncology-related skincare conditions; and Cannabinoid and COX-2 inhibitor Conjugation. The ENVB average annual return since 2015 is shown above.
The Average Annual Return on the ENVB average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ENVB average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ENVB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|